PTO Issues New Patent to Star Scientific Covering Synthesis of Anatabine


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Star Scientific, Inc. (NASDAQ: CIGX) announced today that the U.S. Patent and Trademark Office ("PTO") has issued Patent No. 8,207,346 (the "346 patent") to the company's wholly owned subsidiary, Rock Creek Pharmaceuticals, Inc.  This patent covers an improved method for synthesizing anatabine that facilitates large scale commercial production of high purity anatabine.   Anatabine citrate is the active ingredient in Anatabloc®, the dietary supplement manufactured by Rock Creek Pharmaceuticals that is designed to support the immune system in maintaining healthy levels of inflammation.  As previously announced, the PTO issued a Notice of Allowance on May 11, 2012 to Rock Creek Pharmaceuticals for this synthesis process; however, today's issuance marks an official grant of the patent to the company.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDALegal